First Patient Enrolled in AlloSure Registry

BRISBANE, Calif., Feb. 01, 2018 -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announces that the first patient was enrolled in the Kidney Allograft Outcomes AlloSure Registry (K-OAR) on January 31.

AlloSure launched on October 9, 2017 with Medicare coverage, and over 30 transplant centers across the United States have ordered AlloSure for their patients. To collect longer term outcome data, K-OAR will capture one, two, and three year follow up data on patients from 35 centers that use AlloSure in a routine testing schedule that begins surveillance 1 month after the transplant. Dr. Tambi Jarmi, the principle investigator for K-OAR at Tampa General Hospital, enrolled the first kidney transplant patient.

“I am excited to launch this innovative registry to assess longer term clinical outcomes for kidney transplant patients. While most transplant studies focus on 1 year outcomes, we are providing valuable insights with up to 3 year patient follow up. Additionally, we are encouraging all participating centers to adopt a standardized testing protocol to enable better comparisons and analysis of the effects of new testing on outcomes,” said Jim Yee, MD, PhD, Chief Medical Officer at CareDx.

About CareDx
CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products across the transplant testing continuum, including AlloMap® and AlloSure™ for post-transplant surveillance and Olerup SSP®, Olerup QTYPE®, and Olerup SBT™ for pre-transplant HLA testing.

For more information, please visit: www.CareDx.com.

Forward Looking Statements

This press release contains forward-looking statements about our business, research, development and commercialization efforts, including statements regarding K-OAR enrollment and prospects. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including risks associated with successful research, development and planned commercialization of our technologies, that are described in our filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2016 filed by us with the SEC on April 21, 2017 and the periodic reports that we have subsequently filed with the SEC.  Any of these may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

CONTACTS:

CareDx, Inc.
Sasha King
Chief Commercial Officer
415-287-2393
[email protected]

Investor Relations
David Clair
Integrated Corporate Relations, Inc.
646-277-1266
[email protected]